Par Pharmaceutical To Acquire Anchen Pharmaceuticals for $410M Cash

Par Pharmaceutical Companies, Inc. PRX announced today that it entered into a definitive agreement to acquire Anchen Pharmaceuticals, for $410 million in cash.  The transaction is expected to be immediately accretive to non-GAAP earnings in 2011.